IRIS
BUTI, Sebastiano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.658
AS - Asia 16.888
EU - Europa 9.184
SA - Sud America 3.076
AF - Africa 911
Continente sconosciuto - Info sul continente non disponibili 662
OC - Oceania 31
Totale 48.410
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.039
SG - Singapore 6.989
IT - Italia 2.942
VN - Vietnam 2.535
CN - Cina 2.382
BR - Brasile 2.282
BD - Bangladesh 1.690
IE - Irlanda 1.576
HK - Hong Kong 1.425
SE - Svezia 1.259
FR - Francia 664
NL - Olanda 648
ZA - Sudafrica 577
DE - Germania 570
IN - India 363
GB - Regno Unito 289
CA - Canada 284
AR - Argentina 282
FI - Finlandia 228
RU - Federazione Russa 214
AT - Austria 209
IQ - Iraq 158
MX - Messico 157
TR - Turchia 152
JP - Giappone 136
EC - Ecuador 133
IR - Iran 126
ID - Indonesia 124
KR - Corea 108
CO - Colombia 105
PK - Pakistan 97
PH - Filippine 86
ES - Italia 82
UZ - Uzbekistan 80
VE - Venezuela 79
UA - Ucraina 78
PL - Polonia 71
BE - Belgio 70
MA - Marocco 65
PY - Paraguay 61
MY - Malesia 60
CI - Costa d'Avorio 54
TH - Thailandia 53
CL - Cile 52
SA - Arabia Saudita 52
EG - Egitto 46
TN - Tunisia 45
CZ - Repubblica Ceca 41
TW - Taiwan 40
UY - Uruguay 28
JO - Giordania 27
KE - Kenya 27
LT - Lituania 27
AU - Australia 26
PE - Perù 26
AE - Emirati Arabi Uniti 25
AL - Albania 24
AZ - Azerbaigian 23
BO - Bolivia 23
CR - Costa Rica 21
DK - Danimarca 21
DO - Repubblica Dominicana 21
HN - Honduras 20
JM - Giamaica 20
NP - Nepal 20
IL - Israele 19
KZ - Kazakistan 19
RO - Romania 18
SV - El Salvador 17
CH - Svizzera 16
ET - Etiopia 16
PS - Palestinian Territory 16
GT - Guatemala 15
PA - Panama 15
BG - Bulgaria 14
DZ - Algeria 14
OM - Oman 13
RS - Serbia 13
EE - Estonia 12
LB - Libano 12
PT - Portogallo 12
TT - Trinidad e Tobago 12
BH - Bahrain 11
HU - Ungheria 11
NI - Nicaragua 11
GR - Grecia 10
LU - Lussemburgo 10
NG - Nigeria 10
QA - Qatar 10
SN - Senegal 10
AO - Angola 9
BY - Bielorussia 9
HR - Croazia 9
KW - Kuwait 8
BB - Barbados 7
MD - Moldavia 7
PR - Porto Rico 7
KG - Kirghizistan 6
XK - ???statistics.table.value.countryCode.XK??? 6
LV - Lettonia 5
Totale 47.646
Salva come PNG Salva come JPEG
Città #
Singapore 3.318
Ashburn 2.145
San Jose 1.993
Chandler 1.909
Dublin 1.558
Hong Kong 1.360
Santa Clara 1.255
Dallas 1.252
Council Bluffs 974
Ho Chi Minh City 820
Boardman 724
Beijing 602
Hanoi 598
New York 517
Johannesburg 513
Milan 471
Lauterbourg 447
Los Angeles 410
Princeton 298
Rome 260
Shanghai 229
São Paulo 217
Munich 200
Buffalo 182
Parma 162
Vienna 161
Bologna 155
Helsinki 128
Ann Arbor 122
Hefei 116
Nuremberg 107
Des Moines 104
Haiphong 103
Da Nang 100
Chicago 97
Columbus 95
Frankfurt am Main 95
Moscow 93
Tehran 92
Atlanta 90
Tokyo 85
Rio de Janeiro 80
London 79
Turku 78
Naples 75
Orem 71
Phoenix 70
Wilmington 70
Montreal 69
Tashkent 67
Seattle 65
Denver 64
Toronto 64
Brooklyn 63
San Francisco 57
Baghdad 55
Marseille 55
Abidjan 54
Curitiba 53
Warsaw 53
Brussels 51
Chennai 51
Jakarta 51
Boston 50
Bremen 50
Modena 48
Verona 48
Quito 47
Biên Hòa 46
Florence 46
Mexico City 46
Turin 46
Dhaka 44
Belo Horizonte 43
Genoa 43
Amsterdam 42
The Dalles 42
Brasília 39
Houston 39
Guayaquil 38
Guangzhou 37
Hải Dương 37
Pune 37
Seoul 36
Stockholm 36
Figino 35
Tianjin 35
Poplar 33
Istanbul 32
Jacksonville 32
Lahore 31
Can Tho 30
Mumbai 30
Catania 29
Charlotte 29
Dearborn 29
New Delhi 29
Asunción 28
Kuala Lumpur 28
Reggio Emilia 28
Totale 26.950
Salva come PNG Salva come JPEG
Nome #
Adjusted Skeletal Muscle Index (aSMI) correlates with outcome in metastatic Renal Cancer Cell (mRCC) patients (pts) treated with first line (1L) immunotherapy (IT) 820
LBA77 Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial 305
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 247
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 220
1895P Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15) 219
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 209
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 204
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 200
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 198
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 196
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 194
External validation of the novel prognostic Meet-URO score in Metastatic Renal Cell Carcinoma on First Line Immune-combination therapy. - Proceedings from the Second International Urology Cancer Summit, 27th September, Portsmouth, UK 190
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 190
New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?—a narrative review 189
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 189
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study 188
Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study. 187
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 184
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 181
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 180
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27 179
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 178
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 178
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 176
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma 175
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 169
Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations 167
READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) 166
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 165
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 161
Review on radiological evolution of COVID-19 pneumonia using computed tomography 161
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 160
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 160
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 159
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab 158
Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial) 158
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors 156
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity 156
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review 156
Real world analysis of peritoneal metastasis from renal cell carcinoma: Meet-Uro 27 study 156
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 156
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 155
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes 154
Clinical parameters for first-line immuno-combinations choice in metastatic renal cell carcinoma (mRCC) patients (pts): the Meet-URO 33 study 153
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 152
1901P Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8) 151
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset 151
Molecular classification using Lund University algorithm and clinical correlations in muscle-invasive bladder cancer: Insights from a retrospective study 149
Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinoma. 149
Combined standard immunosuppression and immune checkpoint inhibition for BKPyV+ metastatic renal cell carcinoma of the graft in a kidney transplant recipient with chronic rejection: a case report 148
Chronically administered immunotherapy with low-dose IL-2 and IFN-α in metastatic renal cell carcinoma: A feasible option for patients with a good prognostic profile 148
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma 148
Papillary Renal Cell Carcinoma (pRCC): Outcomes of patients receiving first-line immune-based combinations or Tyrosine Kinase Inhibitors (TKIs) from the ARON-1 study 148
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 147
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 146
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 146
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 146
Small renal masses (≤ 4 cm): differentiation of oncocytoma from renal clear cell carcinoma using ratio of lesion to cortex attenuation and aorta–lesion attenuation difference (ALAD) on contrast-enhanced CT 146
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 145
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project 144
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 144
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 143
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 143
Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial. 143
Immunotherapy options in metastatic renal cell cancer: Where we are and where we are going 142
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors 140
1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a) 140
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 139
112 Circulating and molecular markers of inflammation: impact on treatment response and survival among older patients with cancer treated with immune checkpoint inhibitors 139
THE ROLE OF BLOOD CHOLESTEROL QUALITY IN PATIENTS WITH ADVANCED CANCER RECEIVING IMMUNE CHECKPOINT INHIBITORS 137
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 137
The Role of CT Imaging in Characterization of Small Renal Masses 134
The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative review 134
P254 REAl-world Data from an Italian Compassionate Use Program (CUP) of avelumab first- Line Maintenance (1LM) for locallY advanced or metastatic Urothelial Carcinoma (la/mUC): Outcomes from the READY study in patients (pts) with low tumor burden 133
External Validation of the GRade, Age, Nodes and Tumor (GRANT) Score for Patients with Surgically Treated Papillary Renal Cell Carcinoma 133
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 131
7 Tamoxifen vs tamoxifen plus 13-cis-retinoic acid vs tamoxifen plus interferon α-2° as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomized multicentre trial 131
1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study 130
Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients 129
Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon α-2a as first-line endocrine treatments in advanced breast cancer: Updated results of a phase II, prospective, randomised multicentre trial 129
Time to treatment failure (TTF) and treatment beyond progression (TBP) as survival outcome and therapeutic strategy of clinical benefit in pretreated metastatic renal cell carcinoma (mRCC) patients receiving nivolumab: a subanalysis of Meet-URO 15 study. 128
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy 127
1981P Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis 126
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score 126
1716P Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1) 125
Deciphering the different patterns of acquired resistance in immunotherapy treated NSCLC patients through an integrated clinical and blood immuneinflammatory profiling 125
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 124
A wide skull osteolytic metastasis in advanced breast cancer 124
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study) 124
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 122
External validation of the GRade, Age, Nodes and Tumor (GRANT) score for patients with surgically treated papillary renal cell carcinoma. - Proceedings from the Second International Urology Cancer Summit, 27th September, Portsmouth, UK. 122
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy 121
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations 121
Percutaneous Ablation of T1 Renal Masses: Comparative Local Control and Complications after Radiofrequency and Cryoablation 121
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 121
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 120
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program 120
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 120
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 120
Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC) 120
Totale 16.154
Salva come PNG Salva come JPEG
Categoria #
all - tutte 188.622
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 188.622
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.457 0 10 13 30 5 117 319 100 61 25 100 677
2022/20236.059 710 740 558 380 457 586 80 316 1.925 27 203 77
2023/20242.659 135 225 103 109 290 542 204 125 178 154 189 405
2024/202510.042 157 697 754 408 903 1.145 418 456 1.254 1.204 727 1.919
2025/202625.131 1.633 1.890 3.179 2.016 2.965 1.081 2.523 854 2.758 1.866 2.711 1.655
2026/20272.468 1.068 1.400 0 0 0 0 0 0 0 0 0 0
Totale 48.410